Just in Time for 2026, Rocket Lab Won Its Biggest Contract Ever

Rocket Lab won an $816 million Space Force award (TRKT3) to build 18 missile-tracking satellites as part of the PWSA program, with the tranche totaling $3.5 billion split equally among four primes. The deal, plus anticipated ~$1 billion in ancillary parts and services (including StarLite sensors from Rocket Lab’s 2025 GEOST acquisition), could lift Rocket Lab’s participation to roughly $1.8 billion — more than three times trailing-12-month revenue and implying ~82% of TTM revenue per year through deployment by 2029. Despite the revenue lift and a 17% stock bump since the announcement, Rocket Lab remains unprofitable, trades near ~70x trailing sales, and has lower gross margins on space-systems (31.4%) than launch (36.6%), tempering near-term profit upside.

Analysis

Market structure: The $816M TRKT3 award (part of a ~$3.5B tranche) makes RKLB a de facto peer to LMT, NOC and LHX on PWSA work and creates both prime-contractor revenue and supplier aftermarket upside (company cites ~ $1B incremental parts revenue; total ~$1.8B). Spread over 4 years to 2029 this implies ~82% of RKLB’s trailing-12m revenue per year and is already pricing a re-rating (stock +17%); expect upward pressure on small-cap space valuations and modest credit-spread tightening for large defense primes.

Risk assessment: Key tail risks are congressional budget cuts or program reshapes, schedule slippage/cost overruns, integration risk from the recent GEOST acquisition, and export/regulatory constraints on sensors — any of which could wipe >50% of the incremental NPV. Short-term (days/weeks) expect volatility around contract milestones and guidance; medium-term (6–18 months) delivery and manufacturing capacity are the bottleneck; long-term (2027–2029) cashflow depends on milestone recognition and margin mix (launch margin 36.6% vs space systems 31.4%).

Trade implications: Direct play: asymmetric allocation to RKLB (small tactical long 2–3% position) while hedging execution risk with a 25% stop or buying call spreads; conservative core exposure to LMT/NOC/LHX (+1–2% overweight across primes) for durable cashflows. Options: implement 12–18 month RKLB call spreads (buy Jan‑2027 ATM, sell Jan‑2027 +40% OTM) to capture re-rating with limited premium. Pair trade: long RKLB / short LHX sized 3:1 to express small‑cap rerating vs mature prime that already discounts PWSA.

Contrarian angles: Consensus overweights headline revenue; miss is that satellite work gives lower gross margins and heavy capex — the market may be underpricing execution risk and deferred revenue recognition. Historical parallels (defense satellite programs) show big awards frequently produce multi-year cost and schedule overruns, so don’t size positions without milestone-based scaling. Watch for StarLite adoption by rivals (if >50% tranche uses StarLite, upgrade target multiple; if not, downgrade).

Key Decisions for Investors

• Establish a tactical 2–3% long position in Rocket Lab (RKLB) now, target 40–70% upside over 12–24 months, set a hard stop-loss at 25% from entry and scale out on any 50%+ move.
• Buy a financed call spread on RKLB to limit downside: buy Jan‑2027 ATM call and sell Jan‑2027 call 40% above (size to risk 1% of portfolio), capturing re‑rating while capping premium.
• Overweight large defense primes (Lockheed LMT, Northrop NOC, L3Harris LHX) by +1–2% combined for stable cashflows; prioritize LMT for balance sheet resilience and expect modest credit‑spread tightening.
• Initiate a pair trade: long RKLB / short LHX at a 3:1 notional ratio to express small‑cap rerating vs mature prime; reduce if RKLB fails to announce >$500M supplier bookings or misses FY guidance within next 90 days.
• Monitor specific catalysts in the next 30–60 days: (1) RKLB quarterly bookings and DoD milestone payment schedule (trigger: >$300M booked in a quarter to add size), (2) announced StarLite supply contracts with peers (if >50% TRKT3 adoption, add), and (3) any DoD budget amendments or GAO program reviews (if negative, reduce exposure).